Role of Chelating Agentsby
Ralph S.
the toxic effects of cisplatin treatment. However, tumor cells that are resistant to electrophilic antineoplasticagents... ).
Historically, the drug of choice in treatment of lead toxicity is EDTA (disodium ethylenetetraacetate) ( 1,3 ). The common
Being Sick and Breastfeedingby
Becka S
, Mevacor, Pravacor, Zocor
Used to lower the level of cholesterol in the blood
Antineoplasticagents
Used... medicine you take. Here is a list from babycentercom regarding what drugs are safe and what aren’t safe. As always, you
New cancerdrug nearing the end ...by
Medical Quack
New cancerdrug nearing the end of clinical trials, so the FDA has move this up to prioritize the evaluation process for the new potential cancerdrug to treat prostate, lung and breast cancer. It is being developed to work
Where do all the cancerdrugs st ...by
Medical Quack
Where do all the cancerdrugs stand...with the recent news of Ted Kennedy, this article briefly goes over....
A wave of cancerdrugs that target a molecule called VEGF appears especially promising,Timothy Cloughesy, director
Provenge – the Verdict is Near for Dendreon’s Prostate CancerDrugby
Medical Quack
Pharmaceuticals' Degarelix for Advanced Prostate Cancer
Prostate CancerDrug from OncoGenex, Isis Prolongs Lives - Another Prostate cancerdrug Degarelix reduces testosterone levels in as little as 3 days
New Online Calculator for Prostate
NORA : NORA Symposium 2008 Poster 024 | CDC/NIOSH Surfaces where antineoplasticdrugs are handled are known to be contaminated with antineoplasticdrugs. ... The wipe samples were analyzed for 6 antineoplasticdrugs (Table 2) ...
AntineoplasticDrugs - HealthCentral Everything you need to know about antineoplasticdrugs. Information about common uses, side effects, interactions, dosages and storage.
Lupron Inj Precautions and Side Effects Lupron side effects, dosage, and drug interactions. All accurate, up-to-date information is written for the consumer by healthcare professionals.
News
Celator Pharma's Combiplex technology platform gets US patent Celator Pharmaceuticals announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent covering the company's CombiPlex technology platform (US patent application 10/417,631), the basis for the company's product pipeline which includes two clinical-stage products for acute myeloid leukaemia and colorectal cancer.